Details of the Drug

General Information of Drug (ID: DMH5MVE)

Drug Name
Sodium stibogluconate
Synonyms Lenocta; Sodium stibogluconate (cancer); VQD-001; Sodium stibogluconate (cancer), Greenwich; Sodium stibogluconate (cancer), VioQuest
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Leishmaniasis 1F54 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Affected Organisms
Humans and other mammalsProtozoa
ATC Code
P01CB02: Sodium stibogluconate
P01CB: Antimony compounds
P01C: AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
P01: ANTIPROTOZOALS
P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Structure
3D MOL 2D MOL
Cross-matching ID
PubChem CID
16683012
UNII
APJ6285Y89
DrugBank ID
DB05630
TTD ID
D09BBW
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leishmania DNA topoisomerase I (Leishm TOP1) TTNJKC3 Q9NJG8_LEIDO Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Gene/Protein Processing [4]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [5]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Gene/Protein Processing [6]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Gene/Protein Processing [7]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Gene/Protein Processing [5]
Interferon gamma receptor 1 (IFNGR1) OTCTQBWW INGR1_HUMAN Gene/Protein Processing [8]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [5]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Gene/Protein Processing [5]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Gene/Protein Processing [5]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008 Aug;29(8):881-90.
2 Leishmaniasis in Norway. Tidsskr Nor Laegeforen. 2021 Feb 22;141(3).
3 Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
4 SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 2016 Nov 1;310:41-50. doi: 10.1016/j.taap.2016.08.014. Epub 2016 Aug 18.
5 Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. Immunology. 2010 Jun;130(2):193-201. doi: 10.1111/j.1365-2567.2009.03223.x. Epub 2010 Jan 22.
6 Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy. Br J Haematol. 1998 Mar;100(4):720-4. doi: 10.1046/j.1365-2141.1998.00624.x.
7 Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia. 2002 Nov;16(11):2285-91. doi: 10.1038/sj.leu.2402692.
8 Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol. 2003 Apr;97(3):245-57. doi: 10.1179/000349803235001714.